Bioventus (BVS)
(Delayed Data from NSDQ)
$5.40 USD
-0.06 (-1.10%)
Updated May 10, 2024 04:00 PM ET
After-Market: $5.42 +0.02 (0.37%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Income Statements
Fiscal Year end for Bioventus Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 512 | 512 | 431 | 321 | 321 |
Cost Of Goods | 184 | 181 | 128 | 88 | 88 |
Gross Profit | 328 | 331 | 303 | 234 | 234 |
Selling & Adminstrative & Depr. & Amort Expenses | 410 | 582 | 291 | 212 | 212 |
Income After Depreciation & Amortization | -82 | -251 | 12 | 21 | 21 |
Non-Operating Income | 1 | 13 | -3 | 4 | 4 |
Interest Expense | 41 | 26 | 1 | 10 | 10 |
Pretax Income | -121 | -264 | 8 | 16 | 16 |
Income Taxes | 0 | -51 | -2 | 1 | 1 |
Minority Interest | -39 | -55 | -10 | -2 | -2 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -121 | -213 | 10 | 15 | 15 |
Extras & Discontinued Operations | -74 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -156 | -159 | 19 | 16 | 16 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -24 | -184 | 47 | 50 | 21 |
Depreciation & Amortization (Cash Flow) | 57 | 67 | 35 | 29 | 0 |
Income After Depreciation & Amortization | -82 | -251 | 12 | 21 | 21 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 62.65 | 61.39 | 45.47 | 4.90 | NA |
Diluted EPS Before Non-Recurring Items | 0.02 | 0.17 | 0.75 | 7.56 | NA |
Diluted Net EPS (GAAP) | -2.49 | -2.59 | -0.15 | 0.89 | 0.89 |
Fiscal Year end for Bioventus Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 135.42 | 120.79 | 137.07 | 119.06 |
Cost Of Goods | NA | 49.12 | 41.94 | 47.95 | 45.14 |
Gross Profit | NA | 86.30 | 78.85 | 89.12 | 73.92 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 85.13 | 76.44 | 82.37 | 165.97 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.17 | 2.41 | 6.75 | -92.05 |
Non-Operating Income | NA | 0.71 | -0.49 | -0.51 | 1.59 |
Interest Expense | NA | 10.28 | 10.12 | 10.59 | 9.69 |
Pretax Income | NA | -8.41 | -8.19 | -4.35 | -100.16 |
Income Taxes | NA | -0.75 | 0.60 | 0.38 | -0.15 |
Minority Interest | NA | -1.56 | -1.49 | -1.05 | -35.30 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -7.66 | -8.79 | -4.73 | -100.02 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | -74.43 |
Net Income (GAAP) | NA | -6.10 | -7.30 | -3.68 | -139.15 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 63.10 | 62.82 | 62.55 | 62.13 |
Diluted EPS Before Non-Recurring Items | NA | 0.07 | 0.05 | 0.14 | -0.26 |
Diluted Net EPS (GAAP) | NA | -0.07 | -0.12 | -0.06 | -2.24 |